Abilify Maintena

RSS

aripiprazole

Authorised
This medicine is authorised for use in the European Union.

Overview

Abilify Maintena is an antipsychotic medicine that contains the active substance aripiprazole. It is used for the maintenance treatment of schizophrenia in adults whose disease has already been stabilised with aripiprazole taken by mouth.

Schizophrenia is a mental illness with a number of symptoms, including disorganised thinking and speech, hallucinations (hearing or seeing things that are not there), suspiciousness and delusions (false beliefs).

This EPAR was last updated on 02/12/2020

Authorisation details

Product details
Name
Abilify Maintena
Agency product number
EMEA/H/C/002755
Active substance
aripiprazole
International non-proprietary name (INN) or common name
aripiprazole
Therapeutic area (MeSH)
Schizophrenia
Anatomical therapeutic chemical (ATC) code
N05AX12
Publication details
Marketing-authorisation holder
Otsuka Pharmaceutical Netherlands B.V.
Revision
18
Date of issue of marketing authorisation valid throughout the European Union
14/11/2013
Contact address

Herikerbergweg 292
1101 CT Amsterdam
Netherlands

Product information

27/10/2020 Abilify Maintena - EMEA/H/C/002755 - II/0035

Contents

Please note that the size of the above document can exceed 50 pages.

You are therefore advised to be selective about which sections or pages you wish to print.

Pharmacotherapeutic group

Psycholeptics

Therapeutic indication

Maintenance treatment of schizophrenia in adult patients stabilised with oral aripiprazole.

Assessment history

How useful was this page?

Add your rating
Average
1 rating
3 ratings